RESUMEN
Wound necrosis and secondary infection are common complications after Naja atra bites. Clinical tools to evaluate the infection risk after Taiwan cobra bites are lacking. In this Cobra BITE study, we investigated the prevalence of wound infection, bacteriology, and corresponding antibiotic usage in patients presenting with Taiwan cobra snakebites. Patients with wound infection lacking tissue necrosis were included in developing Cobra BITE score utilizing univariate and multiple logistic regression, as patients with wound necrosis require antibiotics for infection treatment. 8,295,497 emergency department visits occurred in the span of this study, with 195 of those patients being diagnosed as having cobra bites. Of these patients, 23 had wound necrosis, and 30 had wound infection, resulting in a wound infection rate of 27.2% (53/195). Enterococcus faecalis and Morganella morganii were the main bacteria identified in the culture report regardless of whether patients' wounds had necrosis. As per our Cobra BITE score, the three factors predicting secondary wound infection after cobra bites are hospital admission, a white blood cell count (in 103/µL) × by neu-trophil-lymphocyte ratio value of ≥114.23, and the use of antivenin medication. The area under the receiver operating characteristic curve for the Cobra BITE score system was 0.88; ideal sensitivity and specificity were 0.89 and 0.76. This scoring system enables the assessment of wound infections after N. atra bites, and it could be modified and improved in the future for other Naja spp. bites.
Asunto(s)
Antibacterianos/uso terapéutico , Antivenenos/uso terapéutico , Venenos Elapídicos/antagonistas & inhibidores , Enterococcus faecalis/efectos de los fármacos , Morganella morganii/efectos de los fármacos , Naja naja , Mordeduras de Serpientes/tratamiento farmacológico , Infección de Heridas/tratamiento farmacológico , Adulto , Anciano , Animales , Técnicas de Apoyo para la Decisión , Venenos Elapídicos/inmunología , Enterococcus faecalis/aislamiento & purificación , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Morganella morganii/aislamiento & purificación , Necrosis , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Mordeduras de Serpientes/diagnóstico , Mordeduras de Serpientes/microbiología , Resultado del Tratamiento , Infección de Heridas/diagnóstico , Infección de Heridas/microbiologíaAsunto(s)
Compuestos de Azabiciclo/uso terapéutico , Aztreonam/uso terapéutico , Bacteriemia/tratamiento farmacológico , Ceftazidima/uso terapéutico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Morganella morganii/efectos de los fármacos , beta-Lactamasas/genética , Antibacterianos/uso terapéutico , Bacteriemia/microbiología , Cefalosporinasa/genética , Preescolar , Combinación de Medicamentos , Infecciones por Enterobacteriaceae/microbiología , Femenino , Neoplasias Hematológicas , Humanos , Pruebas de Sensibilidad Microbiana , Morganella morganii/genética , Morganella morganii/aislamiento & purificaciónRESUMEN
Morganella morganii is a rare cause of peritonitis in patients on peritoneal dialysis (PD). Most of the reported cases have resorted to a switch to hemodialysis. We herein report a case of peritonitis due to M. morganii resistant to third-generation cephalosporins, which was treated successfully with intraperitoneal (IP) tobramycin followed by oral ciprofloxacin. Early microbiologic diagnosis is essential in the treatment of peritonitis from rare microorganisms such as Morganella morganii, and appropriate antibiotic therapy is the key to avoiding catheter loss and subsequent switch to hemodialysis.
Asunto(s)
Ciprofloxacina/administración & dosificación , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Diálisis Peritoneal/efectos adversos , Peritonitis/tratamiento farmacológico , Peritonitis/microbiología , Tobramicina/administración & dosificación , Centros Médicos Académicos , Administración Oral , Cefalosporinas/administración & dosificación , Farmacorresistencia Microbiana , Quimioterapia Combinada , Infecciones por Enterobacteriaceae/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Infusiones Parenterales , Fallo Renal Crónico/diagnóstico , Fallo Renal Crónico/terapia , Persona de Mediana Edad , Morganella morganii/efectos de los fármacos , Morganella morganii/aislamiento & purificación , Diálisis Peritoneal/métodos , Peritonitis/etiología , Resultado del TratamientoRESUMEN
Filipendula ulmaria, also known as meadowsweet, is an herb; its extract was examined for the prevention of histamine production, primarily that caused by contaminated fish. The efficacy of meadowsweet was assessed using two parameters: inhibition of Morganella morganii histidine decarboxylase (HDC) and inhibition of histamine accumulation in mackerel. Ellagitannins from F. ulmaria (rugosin D, rugosin A methyl ester, tellimagrandin II, and rugosin A) were previously shown to be potent inhibitors of human HDC; and in the present work, these compounds inhibited M. morganii HDC, with half maximal inhibitory concentration values of 1.5, 4.4, 6.1, and 6.8 µM, respectively. Application of the extracts (at 2 wt%) to mackerel meat yielded significantly decreased histamine accumulation compared with treatment with phosphate-buffered saline as a control. Hence, F. ulmaria exhibits inhibitory activity against bacterial HDC and might be effective for preventing food poisoning caused by histamine.
Asunto(s)
Filipendula/química , Histamina/metabolismo , Histidina Descarboxilasa/metabolismo , Morganella morganii/efectos de los fármacos , Perciformes/microbiología , Alimentos Marinos/microbiología , Animales , Contaminación de Alimentos/prevención & control , Microbiología de Alimentos , Enfermedades Transmitidas por los Alimentos/prevención & control , Histidina Descarboxilasa/antagonistas & inhibidores , Taninos Hidrolizables/farmacología , Morganella morganii/enzimología , Extractos Vegetales/farmacologíaRESUMEN
A 22-year-old male developed a recurrent sacral abscess associated with embedded shrapnel following a blast injury. Cultures grew extended-spectrum ß-lactamase (ESBL)-producing, carbapenem-susceptible Escherichia coli. Ertapenem was administered, but the infection recurred after each course of antibiotics. Initial surgical interventions were unsuccessful, and subsequent cultures yielded E. coli and Morganella morganii, both nonsusceptible to carbapenems. The isolates were Carba NP test negative, gave ambiguous results with the modified Hodge test, and amplified the bla(OXA48)-like gene by real-time PCR. All E. coli isolates were sequence type 131 (ST131), carried nine resistance genes (including bla(CTX-M-27)) on an IncF plasmid, and were identical by genome sequencing, except for 150 kb of plasmid DNA in carbapenem-nonsusceptible isolates only. Sixty kilobases of this was shared by M. morganii and represented an IncN plasmid harboring bla(OXA-181). In M. morganii, the gene was flanked by IS3000 and ISKpn19, but in all but one of the E. coli isolates containing bla(OXA-181), a second copy of ISKpn19 had inserted adjacent to IS3000. To the best of our knowledge, this is the first report of bla(OXA-181) in the virulent ST131 clonal group and carried by the promiscuous IncN family of plasmids. The tendency of M. morganii to have high MICs of imipenem, a bla(OXA-181) substrate profile that includes penicillins but not extended-spectrum cephalosporins, and weak carbapenemase activity almost resulted in the presence of bla(OXA-181) being overlooked. We highlight the importance of surveillance for carbapenem resistance in all species, even those with intrinsic resistances, and the value of advanced molecular techniques in detecting subtle genetic changes.
Asunto(s)
Escherichia coli/efectos de los fármacos , Escherichia coli/enzimología , Morganella morganii/efectos de los fármacos , Morganella morganii/enzimología , Antibacterianos/farmacología , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Cefalosporinas/farmacología , Electroforesis en Gel de Campo Pulsado , Escherichia coli/genética , Imipenem/farmacología , Pruebas de Sensibilidad Microbiana , Morganella morganii/genética , Plásmidos/genética , beta-Lactamasas/genética , beta-Lactamasas/metabolismoRESUMEN
The intestinal microbiota plays a pivotal role in maintaining human health and well-being. Previously, we have shown that mice deficient in the brush-border enzyme intestinal alkaline phosphatase (IAP) suffer from dysbiosis and that oral IAP supplementation normalizes the gut flora. Here we aimed to decipher the molecular mechanism by which IAP promotes bacterial growth. We used an isolated mouse intestinal loop model to directly examine the effect of exogenous IAP on the growth of specific intestinal bacterial species. We studied the effects of various IAP targets on the growth of stool aerobic and anaerobic bacteria as well as on a few specific gut organisms. We determined the effects of ATP and other nucleotides on bacterial growth. Furthermore, we examined the effects of IAP on reversing the inhibitory effects of nucleotides on bacterial growth. We have confirmed that local IAP bioactivity creates a luminal environment that promotes the growth of a wide range of commensal organisms. IAP promotes the growth of stool aerobic and anaerobic bacteria and appears to exert its growth promoting effects by inactivating (dephosphorylating) luminal ATP and other luminal nucleotide triphosphates. We observed that compared with wild-type mice, IAP-knockout mice have more ATP in their luminal contents, and exogenous IAP can reverse the ATP-mediated inhibition of bacterial growth in the isolated intestinal loop. In conclusion, IAP appears to promote the growth of intestinal commensal bacteria by inhibiting the concentration of luminal nucleotide triphosphates.